ClinicalTrials.gg
RecruitingNCT06561529Updated May 8, 2025

The Gastric Bypass Stent System as a Treatment for Hepatic Fibrosis in Obese Patients in European Region

An interventional study of Gastric Bypass Stent System in Fibrosis and Liver, sponsored by MDCECRO LLC. Recruiting at 2 sites in Latvia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-05-08.

Sponsored by MDCECRO LLC · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The Gastric Bypass Stent System is intended to be used in weight loss treatment for obesity and holds potential as a non-invasive technique for managing hepatic fibrosis. This pilot, prospective, single-arm, clinical investigation aims to evaluate the safety and performance of the Gastric Bypass Stent System for hepatic fibrosis treatment in Europe. This clinical investigation and the ongoing clinical investigation (Protocol number: BL-RD08-040) will be used to evaluate the safety and performance of the investigational device for the intended use.

02

Conditions studied

  • Fibrosis
  • Liver

Browse trials for

03

In context

Fibrosis

1,272 studies on the registry are indexed under Fibrosis; 278 are open to participants now.

This study's planned enrollment of 10 is below the median of 64 across 842 interventional studies indexed under Fibrosis.

Browse Fibrosis studies →

Lead sponsor

MDCECRO LLC is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Subjects who meet all of the following criteria are eligible for this clinical investigation:

  1. Age 18-65 years.
  2. ≥ 30 kg/m².
  3. Medical history suggests suspected or confirmed NASH fibrosis. Meeting any of the following criteria indicates NASH liver fibrosis:

    • Historical biochemical tests for fibrosis: PRO-C3 >14 ng/mL or ELF ≥9
    • Fibroscan, transient elastography ≥8.5 kPa, controlled attenuation parameter ≥280 dB/m
    • Based on existing pathology review, liver within \<2 years before the expected randomization shows stage 1B, 2, or 3 fibrosis NASH, with no significant weight change >5% or medications likely affecting NAS or fibrosis stage.
  4. Liver biopsy confirming NASH within 6 months before the randomization date, with liver biopsy fibrosis stage 1-3, NAS ≥3, and at least a score of 1 for the following NAS components:

    • Steatosis (0-3 points)
    • Ballooning (0-2 points)
    • Lobular inflammation (0-3 points)
  5. Patients who have not achieved effective results after three months of lifestyle modifications and non-invasive treatments (non-diabetic patients have not achieved a weight loss of 5%, diabetic patients have not achieved a weight loss of 3%).
  6. Able and willing to provide for participation in the clinical investigation and comply with all study procedures and assessments.

Subjects who meet any of the following criteria are not eligible for this clinical investigation:

  1. Patients with liver cirrhosis
  2. Patients with secondary obesity; a medical condition that has caused weight gain such as endocrine disorders and hypothalamic disorders.
  3. Chronic, daily use of systemic anti-inflammatory or medications (e.g., ibuprofen, prednisolone) for more than 1 week (not including low-dose aspirin for cardiac prophylaxis or inhaled corticosteroids).
  4. Patients with less than one-year continuous treatment before baseline with hypoglycemic drugs with known weight loss effects (e.g., GLP-1 agonists, SGLT-2 inhibitors, DDP-4 inhibitors).
  5. Patients diagnosed with type 1 diabetes.
  6. Patients with the function of islet β cell basically lost, C-peptide ≤ 1/2 of the normal low limit, or low and flat C-peptide release curve under glucose load.
  7. Patients with significant iron deficiency or iron deficiency anemia upon the Investigator's discretion.
  8. Patients with coagulation dysfunction and chronic, daily use of systemic anti-inflammatory or anti-coagulation medication in the past month (not including low-dose aspirin).
  9. Patients with severe liver and kidney dysfunction, and a serum creatinine concentration ≥ 180 μmol/L.
  10. Patients with Class III heart function of Functional Classification (NYHA) or higher upon the Investigators evaluation.
  11. Patients who have undergone Endoscopic Retrograde Cholangiopancreatography (ERCP) or have a history of cholecystitis or liver abscess, as assessed by medical history and abdominal ultrasound.
  12. Patients with a duodenal ulcer, gastric ulcer, or previous and existing pancreatitis, as assessed by abdominal ultrasound, gastroscopy (prior to the procedure at Visit 3), and medical history.
  13. Patients with gallstones (diameter ≥ 20 mm) with clinical symptoms as assessed by abdominal ultrasound and medical history.
  14. Patients with on-going thyroid dysfunction, not stabilized despite appropriate treatment.
  15. Patients with hemorrhage or potential hemorrhage in the digestive tract.
  16. Patients with gastrointestinal tract anomalies, such as gastrointestinal tract atresia, or other conditions that would result in failed placement in the gastrointestinal tract, as assessed by gastroscopy (prior to the procedure at Visit 3), abdominal digital gastrointestinal radiography, and medical history.
  17. Patients with a history of bowel obstruction or related diseases in the past year.
  18. Patients with a history of systemic lupus erythematosus or scleroderma.
  19. Patients with severe infections that are not controlled.
  20. Patients with poor general condition and having endoscopic (as evaluated by the Investigator).
  21. Pregnant women or planning to become pregnant.
  22. Patients with an alcohol dependence or substance abuse.
  23. Patients with unstable psychiatric disorders.
  24. Patients who are enrolled in another study and have not completed the required follow-up period.
  25. Patients with an allergy to any of the components of the investigational device.
  26. Patients with any other conditions evaluated by the Investigators as unsuitable for participating in the clinical investigation.
  27. Patients who are positive for virus (HBV), virus (HCV), or as determined by antibodies, deoxy/ribonucleic acid (DNA/RNA), or antigens.

Note: Anti-HCV positive, but HCV-RNA negative HCV patients can be included, based on investigator's judgement, if it's not the primary reason for the fibrosis. Anti-HBc positive, but HBs-Ag negative patients can be included, based on investigator's judgement.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Treatment group, subjects will be treated with the Gastric Bypass Stent System implanted

    In total, 10 subjects will be enrolled from 2 investigational sites located in Latvia. Any subject participating in this clinical investigation will not be replaced once withdrawn or lost to follow-up. This study includes 3 phases; screening period, procedural period, and a follow-up period. Following screening, subjects will be treated with the Gastric Bypass Stent System implanted under gastroscopy (Visit 3; Day 0).

    Device: Gastric Bypass Stent System

Interventions

  • DeviceGastric Bypass Stent System

    The Gastric Bypass Stent System is intended to be used in weight loss treatment for obesity holds potential as a non-invasive technique for managing hepatic fibrosis. This clinical investigation will be used to evaluate the safety and performance of the investigational device for the intended use.

06

What researchers measure

Primary outcomes

  1. Change from baseline in Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN score) at 6 months after procedure (i.e. device implantation)

    * Percentage of NAFLD activity score (NAS) reduction without worsening of fibrosis stage; * Percentage of improvement in fibrosis stage and no deterioration in NAFLD activity score (NAS)

    Time frame: 6 months

Secondary outcomes

  1. Relative percentage change in Total Weight Loss (TWL%) and changes in BMI

    Relative percentage change in Total Weight Loss (TWL%) and changes in BMI at 12 weeks after device implantation, at the time of device removal, 12 weeks after device removal, and 24 weeks after device removal.

    Time frame: 12 months

  2. Changes in Fibroscan Controlled Attenuation Parameter (CAP) and Liver Stiffness Measurement (LSM)

    Changes in Fibroscan Controlled Attenuation Parameter (CAP) and Liver Stiffness Measurement (LSM) at 12 weeks after device implantation, at the time of device removal, 12 weeks after device removal, and 24 weeks after device removal.

    Time frame: 12 months

  3. Changes in liver inflammation/injury-related markers (ALT, AST, GGT, ALP, Total Bilirubin, Direct Bilirubin)

    Changes in liver inflammation/injury-related markers (ALT, AST, GGT, ALP, Total Bilirubin, Direct Bilirubin) at 12 weeks after device implantation, at the time of device removal, 12 weeks after device removal, and 24 weeks after device removal.

    Time frame: 12 months

  4. Changes in blood glucose-related markers (fasting insulin, fasting glucose, fasting C-peptide)

    Changes in blood glucose-related markers (fasting insulin, fasting glucose, fasting C-peptide, insulin resistance (HOMA-IR)) at 12 weeks after device implantation, at the time of device removal, 12 weeks after device removal, and 24 weeks after device removal.

    Time frame: 12 months

  5. Changes in blood lipid-related markers (total cholesterol [TC], triglyceride [TG], high-density lipoprotein C [HDL-C], low-density lipoprotein C [LDL-C]), apolipoprotein A1, apolipoprotein B, apolipoprotein CIII, lipoprotein(a))

    Changes in blood lipid-related markers (total cholesterol \[TC\], triglyceride \[TG\], high-density lipoprotein C \[HDL-C\], low-density lipoprotein C \[LDL-C\]), apolipoprotein A1, apolipoprotein B, apolipoprotein CIII, lipoprotein(a)) at 12 weeks after device implantation, at the time of device removal, 12 weeks after device removal, and 24 weeks after device removal.

    Time frame: 12 months

  6. Changes in blood glucose-related markers (insulin resistance (HOMA-IR))

    Changes in blood glucose-related markers (insulin resistance (HOMA-IR)) at 12 weeks after device implantation, at the time of device removal, 12 weeks after device removal, and 24 weeks after device removal.

    Time frame: 12 months

  7. Changes in liver fibrosis-related markers (Forns Index)

    Changes in liver fibrosis-related markers (Forns Index) at 12 weeks after device implantation, at the time of device removal, 12 weeks after device removal, and 24 weeks after device removal.

    Time frame: 12 months

  8. Changes in liver fibrosis-related markers (Fibrosis-4 Index (FIB-4))

    Changes in liver fibrosis-related markers (Fibrosis-4 Index (FIB-4)) at 12 weeks after device implantation, at the time of device removal, 12 weeks after device removal, and 24 weeks after device removal.

    Time frame: 12 months

  9. Changes in liver fibrosis-related markers (S Index)

    Changes in liver fibrosis-related markers (S Index) at 12 weeks after device implantation, at the time of device removal, 12 weeks after device removal, and 24 weeks after device removal.

    Time frame: 12 months

  10. Changes in liver fibrosis-related markers (AST to Platelet Ratio Index (APRI))

    Changes in liver fibrosis-related markers (AST to Platelet Ratio Index (APRI)) at 12 weeks after device implantation, at the time of device removal, 12 weeks after device removal, and 24 weeks after device removal.

    Time frame: 12 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Dec 2025, 18 months after the start.

Of 186 non-industry interventional studies with no phase under Fibrosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 57. This study's planned 18 months is below that.

Counting every sponsor, half of 195 studies reached it within 32 months; a quarter within 18 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2024
First posted
Aug 20, 2024
StartActual
Jun 13, 2024
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
May 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06561529
Lead sponsor
MDCECRO LLC
Collaborators
Hangzhou Tangji Medical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Aug 20, 2024
Start date
Jun 13, 2024
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
May 8, 2025

Study contacts

MDCE CRO
Contact
ask@mdcecro.com
+86 18611648819
Dmitry Luchinin, MD
Contact
Dmitry.luchinin@mdcecro.com
+86 17715569787

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion